Boardroom Alpha
10-Q primary document
ALHC · Quarterly Report (Form 10-Q) · Filed July 30, 2026

Alignment Healthcare Inc10-Q exhibit

exh104amendment_toxemploym.htm
Document

Exhibit 10.4
AMENDMENT TO EMPLOYMENT AGREEMENT
THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), effective as of the Effective Date (defined below), by and between Alignment Healthcare USA, LLC, a California corporation (the “Employer”), and Christopher J. Joyce (the “Employee”).

RECITALS
WHEREAS, Company and Employee are parties to that certain Employment Agreement, effective August 1, 2023 (the “Agreement”);
WHEREAS, as of the Effective Date, Employee is transitioning to report from the Chief Executive Officer to the Executive Vice President – Corporate Affairs; and
WHEREAS, pursuant to and in accordance with Section 19 of the Agreement, Employer and Employee now desire to amend the Agreement in order to effect certain changes to the terms and conditions of Employee’s employment in connection with his new role, as set forth in this Amendment.
AGREEMENT
NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1.1Effective Date. This Amendment shall become effective on the date of full execution.
1.2Amendment to Section 3 of the Agreement. The first sentence of Section 3 of the Agreement shall be amended and restated in its entirety as follows: “During the Employment Period, the Employee shall be employed by Employer on a full-time basis with the title determined exclusively by the Employer, initially as Chief Legal & Administrative Officer, reporting to the Executive Vice President – Corporate Affairs of Employer.
1.3Amendment to Section 6(c) of the Agreement. Section 6(c) of the Agreement shall be amended to add the following subsection (iv) to such section: “(iv) in the event of a Termination without Cause of the Employee pursuant to this Section 6(c) before March 31, 2027, notwithstanding anything to the contrary set forth herein or set forth in any equity grant documentation pertaining to grants made to Employee, the vesting for any equity grant of the Employee outstanding as of the date of Termination shall continue to vest on behalf of Employee without interruption through March 31, 2027.
Defined Terms. Any capitalized term used herein but not otherwise defined shall have the meaning ascribed to such term in the Agreement. All section references in this Amendment are to sections of the Agreement, unless otherwise stated herein.
1



1.4Remainder of Agreement Terms. All remaining provisions of the Agreement shall remain unchanged. In the event of any inconsistency or conflict between any term or condition of the Agreement and this Amendment, the terms of this Amendment shall govern and prevail.
1.5Counterparts. This Amendment may be executed in counterparts, each of which shall be deemed to be an original, but both of which together shall constitute one and the same instrument.
1.6Choice of Law. This Amendment shall be construed and enforced under and be governed as to its validity and effect by the laws of the State of California without regard to the conflict of laws principles thereof.
1.7Entire Agreement. This Amendment, together with the Agreement, constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior agreements, representations, and understandings, whether written or oral.
[Signatures on following page]
2



IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date written below.
ALIGNMENT HEALTHCARE USA, LLC

By: /s/ John Kao    
Name: John Kao
Title:    Chief Executive Officer
Dated: May 7, 2026



By: /s/ Christopher Joyce    
Name: Christopher Joyce, individually
Dated: May 6, 2026




3
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer